Janux Therapeutics (JANX) EBITDA (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of EBITDA data on file, last reported at -$28.1 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$28.1 million, down 28.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$117.7 million (down 60.16% YoY), and the FY2025 annual result was -$111.5 million, down 65.15% from the prior year.
• EBITDA grew to -$28.1 million in Q1 2026 per JANX's latest filing, from -$32.2 million in the prior quarter.
• Over five years, EBITDA peaked at -$7.1 million in Q2 2024 and troughed at -$33.9 million in Q2 2025.
• A 5-year average of -$19.3 million and a median of -$17.2 million in 2022 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2024: EBITDA sank 555.74% in 2022, then surged 60.45% in 2024.
• A 5-year view of EBITDA shows it stood at -$15.3 million in 2022, then surged by 35.27% to -$9.9 million in 2023, then slumped by 160.98% to -$25.9 million in 2024, then declined by 24.37% to -$32.2 million in 2025, then gained by 12.71% to -$28.1 million in 2026.
• Business Quant data shows JANX's EBITDA at -$28.1 million in Q1 2026, -$32.2 million in Q4 2025, and -$23.5 million in Q3 2025.